• Home
  • About Us
  • Platform
  • Pipeline
  • Founders
  • Advisory Board
  • Collaboration Partners
  • Press Releases
  • Contact
    • Home
    • About Us
    • Platform
    • Pipeline
    • Founders
    • Advisory Board
    • Collaboration Partners
    • Press Releases
    • Contact
  • Home
  • About Us
  • Platform
  • Pipeline
  • Founders
  • Advisory Board
  • Collaboration Partners
  • Press Releases
  • Contact

Development Programs

LANA -CF  - Developing a novel long-acting subcutaneous peptide-based therapy for the treatment of Chronic Heart Failure


  • Status - Preclinical Development


LANA-PL - Developing a novel long-acting aerosolized peptide-based therapy for the treatment of pulmonary diseases, including COPD, Asthma, and Pulmonary Hypertention


  • Status - Preclinical Development


LASP - Developing a novel long-acting subcutaneous peptide-based therapy for the treatment of cardiovascular and metabolic diseases


  • Status - Preclinical Development


LASC - Developing a novel long-acting subcutaneous peptide-based therapy for the treatment of cardiovascular diseases


  • Status - Preclinical Development


Copyright © 2021 Antlia Bioscience, Inc. - All Rights Reserved.